# OnCo record nct06890598 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06890598/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06890598", "NCT06890598" ;
  schema:name "Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer"@en ;
  schema:alternateName "SUNRAY-02"@en ;
  schema:description "A phase 3 trial of Olomorasib, Pembrolizumab and Durvalumab in non-small-cell lung cancer, run by Eli Lilly and Company, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06890598/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06890598> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2025-03-27" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/kras-g12c-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kras-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/olomorasib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/durvalumab/> ;
  onco:companies <https://onco.cc/companies/eli-lilly/>, <https://onco.cc/companies/astrazeneca/> .